Confab is a Montreal-based pharmaceutical manufacturing company with licenses from both FDA and European regulatory bodies, as well as certain Asian countries to manufacture drugs for human use.
Global Health Ventures has a proprietary platform technology for drug delivery via the sublingual (under the tongue) route.
In human studies, X-Excite has been shown to reach the blood stream rapidly, producing maximal effect and having less of the unwanted side effects associated with oral delivery route.
X-Excite has completed clinical development in Europe.
The final formulation of the X-Excite drug, which has similar pharmaceutical ingredient as the Pfizer drug Viagra, is now completed and can be produced in large volume.
Global Health Ventures’ ‘Relax-B’ for anxiety is also under development in Canada.
The company plans to use the same technology to deliver a number of other FDA approved and non-approved drugs that require faster delivery, or reduced hepatic and gastrointestinal side effects.
These include stress, sleeping disorders, pain killers, anti-allergy medications, heart and lung medication, migraine and addiction replacement therapies.